BioSpace News Archive

Element Biosciences Inc. today announced a partnership with Agilent Technologies demonstrating integration of Element’s AVITI System with Agilent Technologies’ industry-leading SureSelect target enrichment panels, providing customers greater access to these genomic tools.

Element Biosciences, Inc. today announced a partnership with New England Biolabs (NEB®) to commercially develop and launch products to enable compatibility of the NEBNext Ultra II portfolio with the Element AVITI System.

Element Biosciences, Inc. today announced a partnership with Watchmaker Genomics demonstrating the value and performance of Watchmaker’s DNA and RNA Library Prep Kits on Element’s AVITI System.

Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.

Secarna Pharmaceuticals GmbH & Co. KG today announced that Denali Therapeutics Inc. (“Denali”) has exercised its option to in-license an ASO program generated by Secarna through its proprietary drug discovery and development platform, LNAplusTM.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on March 1, 2022, to provide a business update and review the company’s financial results for the fourth quarter and year ended December 31, 2021.

Acer Therapeutics Inc. announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), today announced a publication in Cancer Research by scientists from the University of Edinburgh titled Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors, highlighting NXP900’s robust activity in preclinical models of Triple Negative Breast Cancer (“TNBC”) with Integrin-Linked Kinase (“ILK”) loss.

TC Biopharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, is pleased to announce the appointment of 4 new members to its Board of Directors.